Group 2E: HER2-negative Breast Cancer; Hormone Therapies; Clinical Trials; Treatment Resistance

Poster #TPS1135: OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors.

Poster #TPS1138: TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).


Jun 12 2024


2:00 pm - 3:30 pm

Zoom Webinar